One Biomed, a Singapore-based diagnostics startup, has established a joint laboratory with the Agency for Science, Technology, and Research’s Genome Institute of Singapore (GIS). The lab is located in Singapore’s Biopolis complex, and will focus on developing multiplexed and syndromic panels that address clinically relevant infectious diseases in Asia. These molecular diagnostics assays will run on One Biomed’s forthcoming platform, which will deploy proprietary technology such as a silicon biophotonics dual-ring sensor and a consumable cartridge design for enhanced portability. The company’s eventual goal is to develop a simple and cost-effective point-of-care molecular testing device.

“Our collaboration with One BioMed helps us to address one of the most difficult problems facing patients and healthcare providers across the region—poor access to accurate testing for infectious diseases like influenza, dengue, and tuberculosis,” said Ng Huck Hui, PhD, executive director of GIS. “This partnership is a great, high impact example of Singapore technology developed to solve clinical challenges which disproportionally affect Asia.”